Current Business: An Investment Analysis Suggests Johnson and Johnsons most recent Coup may not be a Coup at all. This paper is a review of a 13 December 2004 announcement that pharmaceutical behemoth Johnson and Johnson had taken over Guidant, an implantable defibrillator company. The review concludes the takeover does not address the eroding market share J&J is experiencing in the prescription drug market as a result of pending patent expirations and increased competition; hence, the investment analysis concludes this takeover should be viewed cautiously by investors. Pages: 3 Bibliography: 1 source(s) listed Filename: 23401 Currentbusiness.doc Price: 26.85